Haleon shares tumble after Q4 sales miss, cautious 2026 guidance
#Haleon #Q4 sales miss #2026 guidance #London trading #organic sales growth #consumer health #stock performance
📌 Key Takeaways
- Haleon shares fell over 4% in London trading after missing Q4 sales expectations
- Q4 organic sales growth was 2.1%, below the 3.5% consensus estimate
- The company issued cautious 2026 guidance of 3-5% organic sales growth
- Analysts expressed concern about the lowered guidance and performance
📖 Full Retelling
Haleon shares fell more than 4% in early London trading on February 25, 2026, after the consumer health group reported softer-than-expected fourth-quarter organic sales growth and issued a cautious near-term outlook. The company's fourth-quarter organic sales growth reached 2.1%, missing the 3.5% consensus estimates cited by Jefferies, while volume declined 0.3% compared with expectations for growth of around 1%. The company pointed to a 1.5 percentage-point headwind from the cold and flu season, particularly affecting Central Europe, which is expected to remain a drag in the first quarter. North America like-for-like sales fell 1.0%, roughly in line with forecasts, but volumes disappointed at -3.7%, significantly below the company's earlier guidance of around -1% for the region. Emerging markets growth slowed to about 5.7%, down sequentially from 7.1% in the third quarter, with Brazil specifically flagged as an area of weakness. Despite these challenges, Haleon delivered a full-year margin of 22.9%, ahead of the 22.6% consensus. Looking ahead, the company guided to 2026 organic sales growth of 3–5%, below the roughly 4.6% Visible Alpha consensus. Management cited a weak cold and flu season and a challenging consumer environment for the more cautious near-term outlook, while reiterating its medium-term ambition of 4–6% growth beyond this year. Jefferies analyst David Hayes commented, 'This is not good enough we fear. The guide moves down a level to 3-5% (vs mid term guidance of 4-6%). We could expect HLN to be a notable underperformer this AM.'
🏷️ Themes
Corporate Earnings, Market Performance, Healthcare Sector
📚 Related People & Topics
Haleon
British multinational consumer healthcare company
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected ...
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry AMD stock surges 14% on Meta AI partnership deal Gold prices rise 1% as tariff jitters aid haven demand; silver, platinum rally Bitcoin slips, wipes out 50% from October record high at session low Wall Street ends higher on tech rebound ahead of State of the Union address (South Africa Philippines Nigeria) Haleon shares tumble after Q4 sales miss, cautious 2026 guidance By Vahid Karaahmetovic Author Vahid Karaahmetovic Earnings Published 02/25/2026, 03:07 AM Updated 02/25/2026, 03:13 AM Haleon shares tumble after Q4 sales miss, cautious 2026 guidance 0 HLN -3.65% Investing.com -- Haleon shares fell after the consumer health group reported softer-than-expected fourth-quarter organic sales growth and issued a cautious near-term outlook. The stock fell more than 4% in early London trading by 08:12 GMT. Get sharper insight into corporate earnings with InvestingPro Fourth-quarter organic sales growth was 2.1%, missing the 3.5% consensus estimates cited by Jefferies. Volume declined 0.3%, compared with expectations for growth of around 1%, while pricing of 2.4% was broadly in line. The company pointed to a 1.5 percentage-point headwind from the cold and flu season, led by weakness in Central Europe, which is also expected to remain a drag in the first quarter. North America like-for-like sales fell 1.0%, roughly in line with forecasts, but volumes disappointed at -3.7%, a key metric given the company’s earlier guidance of around -1% for the region. Emerging markets growth slowed to about 5.7%, down sequentially from 7.1% in the third quarter, with Brazil flagged as an area of weakness. Haleon delivered a full-year margin of 22.9%, ahead of the 22.6% consensus. Looking ahead, the company guided to 2026 organic sales growth of 3–5%, below the roughly 4.6% Visible Alpha consensus. Management cited a weak cold and flu season and a challenging consumer environment for the more cautious near-term outlook, while reiterati...
Read full article at source